ValGenesis ads, brutally reviewed.
ValGenesis is running 18 live ads on LinkedIn and Google. Their average fit to their own ideal buyer is 6.8 out of 10, and 5 ads need fixing. Each ad below is one of ValGenesis’s real live creatives, read straight from the ad libraries.
ValGenesis’s live ads, scored against their buyer
- From AI Assistance to Governed Execution: Rethinking Control in CQV, scored 7/10 against ValGenesis’s ideal buyer. Sharp, timely hook for validation engineers skeptical of AI governance, but stops short of a concrete outcome or next step.
- Keep the Reasoning With the Record, scored 6/10 against ValGenesis’s ideal buyer. Clever metaphor for CMC knowledge transfer pain, but the value of the 'Reusable CMC Library' is shown not explained, leaving the outcome vague.
- Bring consistent validation to more sites, scored 7/10 against ValGenesis’s ideal buyer. Named customer and product screenshot give strong credibility, but the outcome metric shown (4.9% High Risk Entities, 140 Impact Assessment) needs context to land.
- Clean and Dirty Hold Times: How To Design Studies and Manage Risk, scored 8/10 against ValGenesis’s ideal buyer. Named speaker, specific topic, and clear logistics make this a strong event draw for cleaning validation buyers.
- Explore a Measurable CPV Pilot for Pfizer, scored 7/10 against ValGenesis’s ideal buyer. Named account and sharp pain contrast land well, but no outcome number or proof of CPV impact weakens the close.
- Explore Coordinated Cleaning and Operational Records, scored 7/10 against ValGenesis’s ideal buyer. Named account and unified-approach framing are on-point, but no outcome or proof behind the concept leaves it conceptual.
- Connect teams and evidence across validation, scored 7/10 against ValGenesis’s ideal buyer. Named account and product screenshot give strong ICP fit, but no quantified outcome limits the urgency to act.
- Reduce manual validation work with AI assistance, scored 6/10 against ValGenesis’s ideal buyer. Named account and AI angle are relevant but the value stays generic without a specific time or effort outcome.
- Keep Process Knowledge Connected, scored 7/10 against ValGenesis’s ideal buyer. Named account and lifecycle diagram clearly map the tech-transfer pain, but no proof or outcome number to close the argument.
- Explore Connected Lifecycle Risk with iCMC™, scored 7/10 against ValGenesis’s ideal buyer. Named account and connected-risk diagram speak directly to CMC and QbD buyers, but no proof or quantified outcome to compel action.
- Boost the Efficiency of Your Commissioning and Qualification Processes, scored 6/10 against ValGenesis’s ideal buyer. Topic is squarely on-ICP but 'best practices' framing is generic with no specific insight or proof to earn the click.
- Connect PPQ Context to CPV, scored 7/10 against ValGenesis’s ideal buyer. Sharp PPQ-to-CPV hook lands precisely on the ICP pain, but no outcome or proof to close the gap.
- Explore a Smarter Path for Existing FMEAs, scored 7/10 against ValGenesis’s ideal buyer. Named-account personalization and reusable CMC library concept resonate, but outcome stays abstract with no proof.
- Extend the value of your validation foundation, scored 6/10 against ValGenesis’s ideal buyer. Named-account framing is smart but the value proposition stays generic with no specific outcome or proof.
- Explore Common Governance with Site Flexibility, scored 8/10 against ValGenesis’s ideal buyer. Dual tension of governance vs. site flexibility is the exact multi-site pharma pain, and the product screenshot grounds it.
- Let's Explore Your Next Risk-Management Scenario, scored 6/10 against ValGenesis’s ideal buyer. Provocative risk-change question fits the ICP but the answer stays vague with no outcome or proof shown.
- Build on Merck’s validation experience, scored 7/10 against ValGenesis’s ideal buyer. Reuse-across-sites message hits a real multi-site rollout pain, but no concrete outcome or metric to sharpen the value.
- Connect Knowledge Across Pfizer’s Network, scored 7/10 against ValGenesis’s ideal buyer. Lifecycle knowledge plus site-visibility tension is a precise multi-site pharma pain, but no proof and CTA is generic.
See ValGenesis’s full live-ad board on AdRoast. Every creative scored against their ICP, with the exact fix for each.
Learn the method behind these scores: the AdRoast guides cover how to audit your ads against your ICP and why clicks do not turn into pipeline.